Viatris Inc. (VTRS) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $13.91. It has a SharesGrow Score of 38/100, indicating a weak investment profile with 1 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of VTRS = $52.56 (+277.9% from the current price, the stock appears undervalued). Analyst consensus target is VTRS = $15 (+9.6% upside).
Valuation: VTRS trades at a trailing Price-to-Earnings (P/E) of -4.4 (S&P 500 average ~25).
Financials: revenue is $14.3B, -4.2%/yr average growth. Net income is $3.5B (loss), growing at -603.7%/yr. Net profit margin is -24.6% (negative). Gross margin is 35.1% (-4.9 pp trend).
Balance sheet: total debt is $14.7B against $14.7B equity (Debt-to-Equity (D/E) ratio 1, moderate). Current ratio is 1.3 (adequate). Debt-to-assets is 39.5%. Total assets: $37.2B.
Analyst outlook: 3 / 12 analysts rate VTRS as buy (25%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 60/100 (Pass), Growth 15/100 (Fail), Past 50/100 (Partial), Health 33/100 (Fail), Moat 61/100 (Partial), Future 40/100 (Partial), Income 10/100 (Fail).
